Drugs in development · updated 11 November 2026
CM313: clinical trials and development status
As of 11 November 2026 CM313 is in 6 active clinical trials (recruiting or ongoing, phases I–III) for 5 diseases. The most advanced phase is III.
Authorisation
- EU no (EMA)
- Italy not in the AIFA register
- Germany not available
- US no (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
What it is
A monoclonal antibody directed against the human cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38), with potential antineoplastic activity. Upon administration, lumrotatug specifically targets and binds to CD38 expressed on tumor cells. This may trigger antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP) and apoptosis, resulting in cell lysis and depletion of CD38-expressing tumor cells. In addition, lumrotatug inhibits the extracellular enzyme activity of CD38. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies. It plays an important role in the regulation of migration and receptor-mediated adhesion, as well as various cell functions through its multiple ecto- and endo-enzymatic activities.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Multiple myeloma | III | 1 | NCT07910903 |
| Autoimmune thrombocytopenic purpura | II | 2 | NCT06594146 |
| Aplastic anemia | I–II | 1 | NCT06791824 |
| IgA glomerulonephritis | II | 1 | NCT06830395 |
| Systemic lupus erythematosus | II | 1 | NCT06791772 |
Everything on CM313
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 11 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.